Written and peer-reviewed by physicians—but use at your own risk. Read our disclaimer.

banner image

amboss

Trusted medical answers—in seconds.

Get access to 1,000+ medical articles with instant search
and clinical tools.

Try free for 5 days

Management of tachycardia

Last updated: January 6, 2021

Summary

Tachycardia is defined as a heart rate that exceeds 100/minute. Signs of unstable tachycardia include chest pain, shock, and impaired consciousness. Unstable tachycardia is considered an emergency and should be managed with immediate electrical cardioversion. In stable tachycardias, both the cardiac rhythm (i.e., regular or irregular) and the QRS complex (i.e., narrow-complex tachycardia and wide-complex tachycardias) should be evaluated. Undifferentiated regular supraventricular tachycardia (SVTs) should be initially managed with a trial of vagal maneuvers and, if necessary, IV adenosine. Irregular SVTs are usually caused by atrial fibrillation (Afib) or atrial flutter, which are managed either with a rate control strategy (e.g., with β-blockers or calcium channel blockers) or a rhythm control strategy (i.e., with antiarrhythmics or electrical cardioversion) in combination with risk-based anticoagulation therapy. Undifferentiated wide-complex tachycardias (WCTs) should be managed with electrical cardioversion or pharmacological cardioversion. If a stable patient becomes unstable at any point during management, immediate electrical cardioversion is recommended regardless of the rhythm. The content in this article is organized to first provide management steps for undifferentiated arrhythmias but also includes management for specific rhythms, once identified. Unstable tachycardia without a pulse, ventricular fibrillation, and cardiac arrest are not addressed here (see ACLS).

Management

Initial approach

  1. ABCDE survey
  2. Determine if the patient is stable or unstable
  3. Obtain a 12-lead ECG
  4. Identify and treat the cardiac rhythm according to acute management algorithm

1. ABCDE survey [1]

  • No pulse: Start CPR (see ACLS).
  • Pulse present: Continue stepwise approach through ABCDE and proceed to the next step.

2. Determine if the patient is stable or unstable

Examine patients for unstable signs of tachycardia so that immediate electrical cardioversion can be initiated if indicated.

3. Obtain a 12-lead ECG

  1. Evaluate whether it is a wide-complex tachycardia (WCT) or narrow-complex tachycardia (NCT).
  2. Determine whether the rhythm is regular or irregular (e.g., RR intervals regular or irregular).
  3. Review previous ECGs if available to look for pre-existing abnormalities that may affect treatment choices, e.g.:

4. Identify and treat the cardiac rhythm according to acute management algorithm

Unstable tachycardia with pulse

For unstable tachycardia without a pulse, start CPR (see ACLS).

Signs of unstable tachycardia [1]

Initial management of unstable tachycardia with pulse

Electrical cardioversion [1][4]

Ensure oxygen is turned off or that the flow of oxygen is moved away from the patient during cardioversion since cardioversion may trigger combustion.

Procedural sedation

Do not delay cardioversion for the sake of sedation!

Synchronized electrical cardioversion [1][4][5]

Indications

Steps

  • Preparation and procedural sedation
  • Place paddles or electrode pads firmly on the thorax of the patient (anteroapical or anteroposterior position).
  • Choose the synchronized (SYNC) mode of shock on the defibrillator device.
  • Select the recommended dose of electrical energy according to the patient's cardiac rhythm. [1][4][5]
  • “Clear” the patient.
  • Deliver shock.
  • Reassess the rhythm and check the pulse.

Defibrillation [10]

Indications

Steps

  • Preparation and procedural sedation for cardioversion
  • Place paddles or electrode pads firmly on the thorax of the patient (anteroapical or anteroposterior position).
  • Choose the unsynchronized mode of shock on the defibrillator device.
  • Select the defibrillator dose: 120–200 J biphasic waveform. [1]
  • “Clear” the patient.
  • Deliver shock.
  • Reassess the rhythm and check the pulse.

Subsequent management

Stable, regular narrow-complex tachycardia

Initial management of stable, regular narrow-complex tachycardia [11]

  1. Determine the underlying rhythm.
  2. Consult cardiology for definitive management and follow-up.

Management of undifferentiated SVT [11][12]

  1. Perform vagal maneuvers. [12]
  2. Reassess the rhythm.
  3. If regular or undifferentiated SVT persists despite adenosine, administer one of the following:
  4. If regular or undifferentiated SVT persists despite the above measures:
  5. Consult cardiology for definitive management.

If the patient becomes hemodynamically unstable, perform synchronized electrical cardioversion.

Calcium channel blockers should be avoided if there is any concern for ventricular tachycardia, as they can precipitate ventricular fibrillation.

Differential diagnoses

Differential diagnosis of SVT
Rhythm Typical ECG findings [11][13][14] Acute management
Sinus tachycardia [11][15][16]
Atrioventricular nodal re-entrant tachycardia (AVNRT)

Orthodromic AVRT

Focal atrial tachycardia

Atrial flutter with fixed AV conduction

If it is not possible to differentiate between the different types of SVT and expert consultation is not available, treat tachycardia as undifferentiated SVT.

Stable, irregular narrow-complex tachycardia

Initial management of stable, irregular narrow-complex tachycardia [1]

  1. Determine the underlying rhythm.
  2. Consult cardiology for definitive management and follow-up.

Differential diagnoses

Differential diagnosis of irregular, narrow-complex tachycardia

Rhythm

Typical ECG findings Acute management
Atrial fibrillation with rapid ventricular response
(Afib with RVR)
[6][11][17]
  • Fibrillatory waves
  • Rhythm: irregularly irregular
  • PR intervals: not distinguishable
  • Absent isoelectric baseline
  • Atrial rate > ventricular rate
  • HR is variable; in Afib with RVR: 100–180/min
Atrial flutter with variable conduction [6][11][17]
  • Flutter waves (sawtooth appearance)
  • Rhythm: irregularly irregular
  • PR intervals: not distinguishable
  • Atrial rate > ventricular rate
  • HR is variable; typically 100–180/min
Multifocal atrial tachycardia (MAT) [11][18]
  • P waves: ≥ 3 distinct P-wave morphologies
  • Rhythm: irregularly irregular
  • PR interval: distinguishable and variable
  • Isoelectric baseline present and distinct [6]
  • Atrial rate > ventricular rate
  • HR > 100

Afib is the most common cause of irregular NCT, followed by atrial tachycardia. MAT is an uncommon cause of tachyarrhythmia; it is often associated with congestive heart failure and COPD. [11][19]

Management of multifocal atrial tachycardia [11]

Rhythm control is usually ineffective for MAT. [11]

Stable wide-complex tachycardia

Establishing the underlying rhythm in a patient with wide-complex tachycardia can be extremely challenging and requires a multifaceted approach. The most critical aspect is to distinguish between ventricular tachycardia (VT) and SVT with accessory pathway, but if this cannot be done in a timely manner any wide-complex tachycardia should be treated as VT, as wide-complex tachycardias are most commonly caused by ventricular arrhythmias. Ventricular fibrillation is an unstable rhythm and is not addressed here. [11][20]

Initial management of stable wide-complex tachycardia

  1. Attach defibrillator pads to the patient.
  2. Ensure that the rhythm is stable.
  3. Check 12-lead ECG and perform a brief, focused history (if there is time).
  4. Determine whether the rhythm is more likely to be ventricular or supraventricular in origin (e.g., Brugada criteria) [1]
  5. Urgent cardiology consultation for definitive rhythm identification, management, and follow-up (see differential diagnoses of wide-complex tachycardia)
  6. Identify and treat the underlying cause (e.g., cardiac glycoside poisoning, myocardial ischemia).

If it is not possible to quickly identify the underlying rhythm as SVT or VT, it is safest to treat empirically as VT with synchronized electrical cardioversion (100 J) or with IV procainamide.

Adenosine and AV nodal blocking agents are contraindicated in unstable, irregular, and polymorphic (e.g., Torsades des pointes) wide-complex tachycardias. In SVT with accessory pathway (e.g., Afib with WPW), the AV blockade caused by adenosine can lead to V-Fib due to unrestricted conduction of rapid atrial impulses through the accessory pathway.

Differentiating between VT and SVT

Brugada criteria [23]
ECG finding VT SVT
Absence of RS in all precordial leads? Yes No
R:S interval > 100 ms in one precordial lead? Yes No
AV dissociation present? Yes No
Morphology consistent with VT in leads V1-2 and V6? Yes No

Interpretation

  • If the answer to any is yes: most likely VT
  • If none are present: most likely SVT

Management of stable, undifferentiated ventricular tachycardia [1][24][25]

Pharmacological cardioversion (IV antiarrhythmics)

Do not administer a second antiarrhythmic without expert consultation. [1]

Adenosine is contraindicated in polymorphic WCT and irregular WCT because of the risk of triggering ventricular fibrillation. Verapamil is contraindicated in WCT because of the risk of profound hypotension and cardiac arrest.

Electrical cardioversion

If it is unclear if a ventricular tachycardia is monomorphic or polymorphic, use defibrillation.

Further management

Differential diagnoses

Differential diagnosis of wide-complex tachycardia
Rhythm Typical ECG findings Acute management
Monomorphic ventricular tachycardia [1][4][24][29]
Polymorphic ventricular tachycardia Undifferentiated polymorphic ventricular tachycardia [1][24][29][30]
  • Rate: 120–300/min
  • Wide QRS complexes with variable morphology
  • Rhythm: usually irregular

Torsades de pointes [1][24][29][30][31]

Brugada syndrome [1][24]
Supraventricular tachycardia (SVT)

SVT with an accessory pathway [1][11][13][21][34]

SVT without an accessory pathway

[1][20][35]

Ventricular pacing (e.g., pacemaker-induced) [36][37][38][39]
  • Pacing spikes are typically present but may be buried.
  • Sensor-driven tachycardia : rate usually ≤ 160–180/minute
  • Pacemaker-mediated tachycardia : rate usually ≤ 160–180/minute
  • Runaway pacemaker : rate usually ≥ 150–200/minute
  • Place a magnet over the pacemaker.
  • Cardiology consult for pacemaker interrogation and troubleshooting
  • Urgent replacement for runaway pacemaker

References

  1. Neumar RW, Otto CW, Link MS, et al. Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010; 122 (18_suppl_3): p.S729-S767. doi: 10.1161/circulationaha.110.970988 . | Open in Read by QxMD
  2. Keating L. Electrocardiographic features of Wolff-Parkinson-White syndrome. Emerg Med J. 2003; 20 (5): p.491-493. doi: 10.1136/emj.20.5.491 . | Open in Read by QxMD
  3. Ali R, Tahir A, Nadeem M, Shakhatreh MI, Faulknier B. Antidromic Atrioventricular Reentry Tachycardia with Wolff Parkinson White Syndrome: A Rare Beast. Cureus. 2018 . doi: 10.7759/cureus.2642 . | Open in Read by QxMD
  4. American Heart Association. Advanced Cardiovascular Life Support: Provider Manual. American Heart Association ; 2016
  5. Link MS, Atkins DL, Passman RS, et al. Part 6: Electrical Therapies: Automated External Defibrillators, Defibrillation, Cardioversion, and Pacing * 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010; 122 (18_suppl_3): p.S706-S719. doi: 10.1161/circulationaha.110.970954 . | Open in Read by QxMD
  6. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. J Am Coll Cardiol. 2014; 64 (21): p.e1-e76. doi: 10.1016/j.jacc.2014.03.022 . | Open in Read by QxMD
  7. Lewis SR, Nicholson A, Reed SS, Kenth JJ, Alderson P, Smith AF. Anaesthetic and sedative agents used for electrical cardioversion. Cochrane Database of Systematic Reviews. 2015 . doi: 10.1002/14651858.cd010824.pub2 . | Open in Read by QxMD
  8. Brown TB, Lovato LM, Parker D. Procedural sedation in the acute care setting.. Am Fam Physician. 2005; 71 (1): p.85-90.
  9. Page RL, Kerber RE, Russell JK, et al. Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: the results of an international randomized, double-blind multicenter trial.. J Am Coll Cardiol. 2002; 39 (12): p.1956-63. doi: 10.1016/s0735-1097(02)01898-3 . | Open in Read by QxMD
  10. Panchal AR, Berg KM, Kudenchuk PJ, et al. 2018 American Heart Association Focused Update on Advanced Cardiovascular Life Support Use of Antiarrhythmic Drugs During and Immediately After Cardiac Arrest: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2018; 138 (23). doi: 10.1161/cir.0000000000000613 . | Open in Read by QxMD
  11. Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia. Circulation. 2016; 133 (14): p.e506–e574. doi: 10.1161/cir.0000000000000311 . | Open in Read by QxMD
  12. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. J Am Coll Cardiol. 2019; 74 (1): p.104-132. doi: 10.1016/j.jacc.2019.01.011 . | Open in Read by QxMD
  13. Blomström-lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias: Executive Summary. Circulation. 2003; 108 (15): p.1871-1909. doi: 10.1161/01.CIR.0000091380.04100.84 . | Open in Read by QxMD
  14. Colucci RA, Silver MJ, Shubrook J. Common types of supraventricular tachycardia: diagnosis and management.. Am Fam Physician. 2010; 82 (8): p.942-52.
  15. Appelboam A, Reuben A, Mann C, et al. Postural modification to the standard Valsalva manoeuvre for emergency treatment of supraventricular tachycardias (REVERT): a randomised controlled trial. Lancet. 2015; 386 (10005): p.1747-1753. doi: 10.1016/s0140-6736(15)61485-4 . | Open in Read by QxMD
  16. Drew BJ, Ackerman MJ, Funk M, et al. Prevention of Torsade de Pointes in Hospital Settings. Circulation. 2010; 121 (8): p.1047-1060. doi: 10.1161/circulationaha.109.192704 . | Open in Read by QxMD
  17. Walls R, Hockberger R, Gausche-Hill M. Rosen's Emergency Medicine. Elsevier Health Sciences ; 2018
  18. Goldberger AL. Clinical Electrocardiography. Mosby ; 2006
  19. Meek S. ABC of clinical electrocardiography: Introduction. II---Basic terminology. BMJ. 2002; 324 (7335): p.470-473. doi: 10.1136/bmj.324.7335.470 . | Open in Read by QxMD
  20. Olshansky B, Sullivan RM. Inappropriate Sinus Tachycardia. J Am Coll Cardiol. 2013; 61 (8): p.793-801. doi: 10.1016/j.jacc.2012.07.074 . | Open in Read by QxMD
  21. B Garner J, M Miller J. Wide Complex Tachycardia - Ventricular Tachycardia or Not Ventricular Tachycardia, That Remains the Question.. Arrhythmia & electrophysiology review. 2013; 2 (1): p.23-9. doi: 10.15420/aer.2013.2.1.23 . | Open in Read by QxMD
  22. Nelson JA, Knowlton KU, Harrigan R, Pollack ML, Chan TC. Electrocardiographic manifestations: wide complex tachycardia due to accessory pathway. J Emerg Med. 2003; 24 (3): p.295-301. doi: 10.1016/s0736-4679(02)00764-3 . | Open in Read by QxMD
  23. Isenhour JL, Craig S, Gibbs M, Littmann L, Rose G, Risch R. Wide-complex Tachycardia: Continued Evaluation of Diagnostic Criteria. Academic Emergency Medicine. 2000; 7 (7): p.769-773. doi: 10.1111/j.1553-2712.2000.tb02267.x . | Open in Read by QxMD
  24. Brugada P, Brugada J, Mont L, Smeets J, Andries EW. A new approach to the differential diagnosis of a regular tachycardia with a wide QRS complex.. Circulation. 1991; 83 (5): p.1649-1659. doi: 10.1161/01.cir.83.5.1649 . | Open in Read by QxMD
  25. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary. Circulation. 2018; 138 (13): p.e210–e271. doi: 10.1161/cir.0000000000000548 . | Open in Read by QxMD
  26. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. J Am Coll Cardiol. 2018; 72 (14): p.e91-e220. doi: 10.1016/j.jacc.2017.10.054 . | Open in Read by QxMD
  27. Ortiz M, Martín A, Arribas F, et al. Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study.. Eur Heart J. 2017; 38 (17): p.1329-1335. doi: 10.1093/eurheartj/ehw230 . | Open in Read by QxMD
  28. Vera A, Cecconi A, Nogales-Romo MT, et al. Wide QRS Complex Tachycardia. Circulation. 2018; 137 (13): p.1407-1409. doi: 10.1161/circulationaha.118.033936 . | Open in Read by QxMD
  29. Eifling M, Razavi M, Massumi A. The evaluation and management of electrical storm.. Texas Heart Institute journal. 2011; 38 (2): p.111-21.
  30. Link MS, Berkow LC, Kudenchuk PJ, et al. Part 7: Adult Advanced Cardiovascular Life Support. Circulation. 2015; 132 (18 suppl 2): p.S444-S464. doi: 10.1161/cir.0000000000000261 . | Open in Read by QxMD
  31. Choudhuri I, Pinninti M, Marwali MR, Sra J, Akhtar M. Polymorphic Ventricular Tachycardia—Part I: Structural Heart Disease and Acquired Causes. Curr Probl Cardiol. 2013; 38 (11): p.463-496. doi: 10.1016/j.cpcardiol.2013.07.001 . | Open in Read by QxMD
  32. ESC Committee for Practice Guidelines, ACC/AHA (Practice Guidelines) Task Force Members. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). Eur Heart J. 2006; 27 (17): p.2099-2140. doi: 10.1093/eurheartj/ehl199 . | Open in Read by QxMD
  33. Dakkak M, Baxi K, Patel A. Beneficial Effects of Isoproterenol and Quinidine in the Treatment of Ventricular Fibrillation in Brugada Syndrome. Case Reports in Cardiology. 2015; 2015 : p.1-5. doi: 10.1155/2015/753537 . | Open in Read by QxMD
  34. Brodie OT, Michowitz Y, Belhassen B, et al. Pharmacological Therapy in Brugada Syndrome. Arrhythmia & Electrophysiology Review. 2018; 7 (2): p.135. doi: 10.15420/aer.2018.21.2 . | Open in Read by QxMD
  35. Fengler BT, Brady WJ, Plautz CU. Atrial fibrillation in the Wolff-Parkinson-White syndrome: ECG recognition and treatment in the ED. Am J Emerg Med. 2007; 25 (5): p.576-583. doi: 10.1016/j.ajem.2006.10.017 . | Open in Read by QxMD
  36. Edhouse J. ABC of clinical electrocardiography: Broad complex tachycardia---Part I. BMJ. 2002; 324 (7339): p.719-722. doi: 10.1136/bmj.324.7339.719 . | Open in Read by QxMD
  37. Safavi-Naeini P, Saeed M. Pacemaker Troubleshooting: Common Clinical Scenarios. Texas Heart Institute Journal. 2016; 43 (5): p.415-418. doi: 10.14503/thij-16-5918 . | Open in Read by QxMD
  38. Alasti M, Machado C, Rangasamy K, et al. Pacemaker‐mediated arrhythmias. Journal of Arrhythmia. 2018; 34 (5): p.485-492. doi: 10.1002/joa3.12098 . | Open in Read by QxMD
  39. Ortega D, Sammartino M, Pellegrino G, et al. Runaway pacemaker: A forgotten phenomenon?. EP Europace. 2005; 7 (6): p.592-597. doi: 10.1016/j.eupc.2005.06.004 . | Open in Read by QxMD
  40. Gul A, Sheikh MA, Rao A. Runaway pacemaker. BMJ Case Reports. 2019; 12 (3): p.e225411. doi: 10.1136/bcr-2018-225411 . | Open in Read by QxMD
  41. Mitchell LB. Empiric Antiarrhythmic Drug Therapy in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. J Am Coll Cardiol. 2009; 54 (7): p.616-617. doi: 10.1016/j.jacc.2009.05.020 . | Open in Read by QxMD
  42. Corrado D, Wichter T, Link MS, et al. Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. Circulation. 2015; 132 (5): p.441-453. doi: 10.1161/circulationaha.115.017944 . | Open in Read by QxMD
  43. Klein I, Danzi S. Thyroid Disease and the Heart. Circulation. 2007; 116 (15): p.1725-1735. doi: 10.1161/circulationaha.106.678326 . | Open in Read by QxMD
  44. Kweon KH, Park BH, Cho CG. The Effects of L-thyroxine Treatment on QT Dispersion in Primary Hypothyroidism. J Korean Med Sci. 2007; 22 (1): p.114. doi: 10.3346/jkms.2007.22.1.114 . | Open in Read by QxMD
  45. Ackerman MJ, Priori SG, Dubin AM, et al. Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent?. Heart Rhythm. 2017; 14 (1): p.e41-e44. doi: 10.1016/j.hrthm.2016.09.012 . | Open in Read by QxMD
  46. Chockalingam P, Crotti L, Girardengo G, et al. Not All Beta-Blockers Are Equal in the Management of Long QT Syndrome Types 1 and 2. J Am Coll Cardiol. 2012; 60 (20): p.2092-2099. doi: 10.1016/j.jacc.2012.07.046 . | Open in Read by QxMD
  47. Dietel M, Suttorp N, Zeitz M, et al.. Harrisons Innere Medizin (2 Bände). ABW Wissenschaftsverlagsgesellschaft (2005) ; 2005
  48. Ben Yedder N, Roux JF, Paredes FA. Troponin Elevation in Supraventricular Tachycardia: Primary Dependence on Heart Rate. Can J Cardiol. 2011; 27 (1): p.105-109. doi: 10.1016/j.cjca.2010.12.004 . | Open in Read by QxMD